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Abstract
OBJECTIVE: The objective of this systematic review is to determine whether fentanyl pectin
nasal spray (FPNS) is safe and effective treatment for patients with breakthrough cancer pain.
STUDY DESIGN: Review of three English language primary randomized controlled trials
published 2010-2011.
DATA SOURCES: Multicenter, randomized, double-blind, double-dummy, placebo-controlled
trials comparing fentanyl pectin nasal spray, immediate-release morphine sulfate, and/or nasal
spray placebo were found using PubMed, COCHRANE, and Medline databases.
OUTCOME MEASURED: All three studies essentially used similar parameters to measure
effectiveness and safety of fentanyl pectin nasal spray compared to oral immediate-release
morphine sulfate and/or placebo. Baseline pain intensity was scored 0-10. Pain intensity (PI) and
pain relief (PR) were measured at 5, 10, 15, 30, 45, 60 minutes in order to assess time intervals
clinically meaningful pain relief and maximum pain relief has been achieved. Adverse events
were also recorded through all phases of the studies, and objective nasal tolerability assessments
were performed.
RESULTS: Collectively, the results demonstrated that clinically meaningful pain relief was
achieved by fentanyl pectin nasal spray in as early as 10 minutes when compared to the control.
Furthermore, approximately half the breakthrough cancer pain episodes achieved maximum pain
relief at 60 minutes with FPNS compared to just over one-third of patients with immediaterelease morphine sulfate. No significant nasal effects were reported, and there were no nasal
tolerability parameters reported at moderate to severe intensity.
CONCLUSION: The three randomized-controlled trials demonstrate that fentanyl pectin nasal
spray is both safe and effective for the treatment of BTCP episodes compared to the current gold
standard of treatment and placebo. The efforts of the studies used have contributed to the FDA
approval of this first intranasal option in 2011for cancer patients suffering from inadequately
managed breakthrough cancer pain.
KEY WORDS: fentanyl, intranasal, patient acceptability, breakthrough cancer pain
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INTRODUCTION
The pain experienced by patients suffering from cancer can often be categorized as one of
two types. Persistent pain, also known as background pain, can be described as constant, having
a gradual onset, and can last up to 12 hours a day.1 This kind of pain can be attributed to mass
effects (cancerous tumors pressing on surrounding bones, nerves, and/or organs), an activated
inflammatory response, or in response to chemotherapy/radiation.1 Conversely, breakthrough
cancer pain (BTCP) strikes suddenly, is unpredictable, peaks at an average of 5 minutes, and
lasts an average of 45 minutes. It is characterized as sharp, shooting, and radiating.1 Although
there is no widely accepted definition, classification system, or assessment tool for this cancer
pain syndrome, it is diagnosed based on the history of several key features such as high intensity
pain, temporal features, precipitating events, and predictability despite otherwise well controlled
background pain.2 These acute episodes of moderate-severe pain “break through” what would
otherwise be tolerated as background pain.
Palliative care is an integral component of care for any cancer patient. BTCP
management presents a challenge for patients and health care providers, because it occurs even
when the patient is taking an appropriate dose of long-acting opioid analgesics on a fixed
schedule. BTCP has been reported to affect up to 80% of all cancer patients with pain.5 Most
patients with BTCP report having pain of severe to excruciating intensity; studies have reported
patients experiencing a median of 1.5-6 episodes per day1, and a maximum of 50 episodes per
day.1 Furthermore, there are 28.2 million primary diagnoses of cancer per year, and the average
inpatient length of stay is 6.3 days.6 Although an exact amount has not been identified regarding
the national expenses related to cancer-related pain management, greater patient satisfaction with

1

Elengical, Fentanyl Pectin Nasal Spray & BTCP

pain control ultimately results in taking less medications, less office visits, and less medical debt
for the patient.
Short-acting opioid “rescue medications”, such as morphine or oxycodone, are common
pharmacologic agents used in the management of BTCP that are used adjunctively to a fixedschedule opioid regimen. Among these medications, the current gold standard is oral immediaterelease morphine sulfate tablets (IRMS).2 However, the discrepancy between the
pharmacodynamics of such rescue medications and the very nature of a BTCP episode is a
commonplace dilemma that hinders adequate pain control and has been well noted throughout
literature. For example, the onset of a typical morphine or oxycodone formulation is at least 20
minutes, with a peak effect at 1 hour; meanwhile, a typical BTCP episode peaks at 5 minutes and
can last about 3 minutes.1 More studies are needed to determine more effective treatments to
alleviate this type of pain in a more timely and patient satisfactory manner.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not fentanyl pectin
nasal spray is safe and effective for the treatment of breakthrough cancer pain.
METHODS
Regarding the literature search, the keywords used in the databases PubMed, Medline,
and Cochrane were limited to fentanyl, intranasal, breakthrough pain, and patient acceptability.
All articles were published in English and peer reviewed journals between the years 2010 and
2011. The author selected the three articles on the basis of featuring patient-oriented outcomes,
rather than disease-oriented outcomes. Table 1 summarizes characteristics of the studies used in
this systematic review.
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All three randomized controlled trials used in this systematic review used the following
criteria to select participants. Patients had to be over the age of 18 with a histologically
confirmed diagnosis of cancer. Also, patients must be receiving a fixed-schedule opioid regimen
at a total daily dose ≥60g/day for background cancer pain, and experience at least 1-4 episodes of
BTCP per day.2,3,4
In these studies, the treatment groups receiving intervention drug, fentanyl pectin nasal
spray (FPNS), were compared to those receiving a control treatment of immediate-release
morphine sulfate (IRMS) and/or nasal spray placebo. The most common opioids used by
participant for background pain control were morphine, fentanyl, oxycodone, and methadone.4
The studies were essentially conducted in four phases: a screening phase, an open-label titration
phase (titration of FPNS to an effective dose between 100µg-800 µg that can successfully treat
two consecutive BTCP episodes without unacceptable adverse events), a double-blind, placebocontrolled, randomized, cross over phase, and post double-blind treatment phase.
Several considerations rendering exclusion of participants from the study included
uncontrolled or rapidly escalating background pain, medical instability, past history of inability
to tolerate fentanyl or other opioids, and any disorder or medication use likely to adversely affect
normal functioning of nasal mucosa. Other exclusion criteria include breakthrough pain not
related to cancer, history of alcohol/substance abuse, treatment with MAOIs, anticipated
treatment with any treatment that may affect pain levels (eg. chemotherapy), and treatment with
another investigational drug within 30 days.2,3,4 The statistics utilized to interpret the data include
relative risk reduction (RRR), absolute risk reduction (ARR), number needed to treat (NNT), and
p-values.
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Table 1. Study Demographics for the Analysis of FPNS in the Treatment of BTCP
Study

Davies2
(2011)

Portenoy3
(2010)

Fallon4
(2011)

Type

DB RCT

DB/DD
RCT

DB/DD
RCT

# pts

Age

Inclusion
Criteria

110

Histologically
confirmed diagnosis of
cancer; receiving a
fixed schedule opioid
regimen at a total daily
18+
dose ≥60mg oral
morphine/day for
background pain; have
1-4 episodes of
moderate-severe
BTCP/day

114

Histologically
confirmed diagnosis of
cancer; receiving a
fixed schedule opioid
regimen at a total daily
18+
dose ≥60mg oral
morphine/day for
background pain; have
1-4 episodes of
moderate-severe
BTCP/day

84

Histologically
confirmed diagnosis of
cancer; receiving a
fixed schedule opioid
regimen at a total daily
18+
dose ≥60mg oral
morphine/day for
background pain; have
1-4 episodes of
moderate-severe
BTCP/day

Exclusion
Criteria
Uncontrolled or rapidly
escalating background
pain; medically
unstable; past inability
to tolerate fentanyl or
opioids; history of EtOH
or substance abuse;
treatment with MAOIs;
any disorder or
medication use likely to
adversely affect normal
functioning of nasal
mucosa
Uncontrolled or rapidly
escalating background
pain; medically
unstable; past inability
to tolerate fentanyl or
opioids; history of EtOH
or substance abuse;
treatment with MAOIs;
any disorder or
medication use likely to
adversely affect normal
functioning of nasal
mucosa
Uncontrolled or rapidly
escalating background
pain; medically
unstable; past inability
to tolerate fentanyl or
opioids; history of EtOH
or substance abuse;
treatment with MAOIs;
any disorder or
medication use likely to
adversely affect normal
functioning of nasal
mucosa

W/D

Interventions

11

Titrated dose
of fentanyl
pectin nasal
spray
between
100-800µg

7

Titrated dose
of fentanyl
pectin nasal
spray
between
100-800µg

5

Titrated dose
of fentanyl
pectin nasal
spray
between
100-800µg

DB= double blind, DD=double dummy

Elengical, Fentanyl Pectin Nasal Spray & BTCP

OUTCOMES MEASURED
The outcomes measured in the studies were patient-oriented outcomes, which reflect
satisfaction with pain management when applying the intervention treatment. The outcomes
measured include the need to use a rescue medication, time at which clinically meaningful pain
relief and maximum pain relief are achieved, adverse events, objective and subjective nasal
tolerability assessments, and patient satisfaction scores.
All three studies collected data via an electronic diary, and objective nasal assessments
were performed by a clinician. All three studies use a modified intent-to-treat (m-ITT) method,
which included all patients in the randomized population who treated at least one BTCP episode
with FPNS and at least one episode with placebo and/or IRMS, and for each of these episodes,
had at least one baseline and one post-baseline pain intensity measurement. All three studies
used an e-diary system, which prompted the participant to rate various measures on a number
scale. Several parameters were used to measure effectiveness; such measures included baseline
pain intensity on a scale of 0-10 (0= no pain, 10= worst possible pain), and pain intensity (PI)
and pain relief (PR) scored at 5, 10, 15, 30, 45, and 60 minutes. PR was measured on a scale of
0-4 (0= none, 4=complete). Patients were also asked to rate overall satisfaction, satisfaction with
speed of onset of PR, satisfaction with reliability, and ease of use and convenience on a scale of
1-4 (1=not satisfied, 4= very satisfied). Also, the need to resort to prescribed rescue medication
was recorded.2,4
To measure safety, adverse events (AEs) were recorded throughout the study. All AEs
that occurred within 24 hours of a FPNS dose were attributed to FPNS use, even though the
patient may have been treated with IRMS soon after. Another measure of safety used was nasal
assessments to explore possibility of local side effects of FPNS use. The study physician
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performed objective nasal assessments to evaluate for nasal obstruction (0=absent; 1= mild
mucosal thickening; 2= moderate edema, narrowing of airways; 3=severe obstruction),
inflammation (0= absent; 1= mild crusting or blood staining; 2= moderate crusting, fresh blood,
pus, or cyanotic mucosa; 3= severe septal perforation or mucosal ulceration), presence of
discharge, and color of mucosa. Subjective nasal assessments were completed via a 10 item
questionnaire, each item rated 0-3 (0= absent, 3= severe). The items rated were stuffy/blocked
nose, runny nose, itching/sneezing, crusting/dryness, burning/discomfort, bleeding nose, cough,
post nasal drip, sore throat, and taste disturbance. Participants we asked to perform this survey
before the first dose of FPNS, 60 minutes after each dose, and at the final study visit.3
RESULTS
All three articles converted continuous data into dichotomous data to adequately assess
effectiveness of FPNS. Two studies (Davies et al. and Fallon et al.) were double-blind-double
dummy RCTs in which patients were treated with FPNS and oral capsule placebo or IRMS and
nasal spray placebo. One RCT (Portenoy et al.) focused on comparing FPNS to a placebo. In
these studies, various pain score endpoints were used to assess whether there was clinically
meaningful pain relief within in a timely manner for the patient (Table 2). Safety was assessed
by the occurrence of AEs and tolerability via nasal assessments.
Of the 110 patients enrolled in the open dose titration phase, 84 patients identified an
effective and tolerable dose of FPNS and were randomly assigned to double-blind treatment in
the Davies et al. study. Based on a per episode analysis at each time interval, the study
demonstrated that FPNS consistently provided statistically significant clinically meaningful pain
relief (≥ 2point pain score reduction from baseline) more rapidly than IRMS in as early as the 10
minute interval, which was reflected in the PID10 scores (p <0.05).2 RRR was calculated to be
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15.4%, the ABI was 7%, and NNT was 15 patients. The NNT indicates that for every 15 patients
treated with FPNS, one more patient would experience a more rapid onset of analgesia than if
treated with IRMS.
In the Fallon et al. study, 84 patients identified an effective and tolerable FPNS dose of
the 110 enrolled in the titration phase. From the79 patients who went on to complete the study, a
total of 372 BTCP episodes treated with FPNS and 368 treated with IRMS were mITTevaluable. Fallon et al. showed that 50.1% of BTCP episodes with FPNS vs. 34.3% BTCP
episodes with IRMS use were rated with a maximum PR score of 4 (0=none, 4=complete pain
relief) at the endpoint of 60 minutes (PR60). This represents a 46.1% (RBI) improvement in
maximal pain relief effectiveness with FPNS use. The NNT conveys that one more patient will
experience complete pain relief by 60 minutes for every 7 patients treated with FPNS as
compared to IRMS use. According to this study, the number of BTCP episodes achieving the
maximum pain relief score of 4 with FPNS was statistically significant from 30 minutes
onwards; however, approximately half the BTCP episodes at 60 minutes achieved maximum
pain relief with FPNS compared to just over one-third of patients with IRMS.4
Another measure relaying effectiveness of FPNS is whether patients needed to use to
their usual rescue pain medication the study. Patients were instructed to resort their rescue pain
medication for any pain that continued to require treatment after 30 minutes after the dose of the
study medication, or any other acute pain other than the target BTCP.3 Overall, 90.6% of the
FPNS-treated versus 80.0% of placebo treated BTCP episodes did not require additional rescue
pain medication within 60 minutes (p<0.001).3 The NNT signifies that for every ten people
treated with FPNS, one more patient did not need to resort to their rescue medication as
compared to the placebo.
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Table 2. Summary of Statistically Significant Endpoints Assessing Pain Relief with FPNS
Study

Endpoint

Davies et al.

PID10

Fallon et al.

PR60

Result
EER=52.4%
CER=45.4%
EER=50.1%
CER=34.3%

No need for
Portenoy et al.

EER=90.6%

rescue med.

CER=80%

use

p-value

RBI

ABI

NNT

<0.05

15.4%

7%

15

<0.0001

46.1%

15.8%

7

<0.001

13.25%

10.6%
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Portenoy et al. assessed the incidence of adverse events (AEs) related to FPNS compared
to an identically appearing nasal spray placebo. Expectedly so, more AEs were reported
following FPNS treatment than following placebo; however, it is important to note that no dosedependent trends could be identified (Table 3a).3 The most commonly reported AEs were
appropriate for opioid therapy in general, and were of mild to moderate severity. Four deaths
occurred following the administration of FPNS, and investigators have associated them with the
progression of disease, rather than the study drug.3 Only 5.3% of patients withdrew from this
study due to adverse events.3 As seen in Table 3b, the NNH of 3 indicate that for every 3 people
treated with FPNS, 1 person will experience an AE when compared to placebo.

Table 3a. Incidence of Common Adverse Events with FPNS in Portenoy et al. Study
FPNS dose:

100µg

200µg

400µg

800µg

Vomiting

6%

1%

4%

1%

Nausea

5%

3%

2%

0%

Dizziness

5%

3%

1%

1%

Epistaxis

1%

2%

2%

2%

Headache

3%

1%

0%

0%
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Table 3b. Statistical Significance of AEs in Portenoy et al. Study

Overall AEs
occurrences

EER

CER

RRI

ARI

NNH

51.3%

5.1%

905%

46.2%

3

Another measure conferring the safety of FPNS is the objective assessments by a
physician and subjective nasal assessments by the patients. In all the studies, no significant nasal
effects were reported. In Davies et al., six patients experienced mild nasal obstruction at
screening, which decreased to two by the end of the study. One patient had severe nasal
discharge and another acquired pale mucosa at screening; however, no patients exhibited these
findings at the study’s end. There were no patients with nasal inflammation during any phase of
the study.2 Subjectively, there were no nasal tolerability parameters reported at moderate to
severe intensity (>2-3 score). Also, there was not a statistically significant difference between
FPNS and IRMS treatments.2 Table 4 explains the distribution of the positive findings on
objective nasal tolerability assessment. There were no findings of moderate to severe rating, so
the results were either “absent” or “present” (mild). There were no trends following increasing
doses of FPNS administered.

Table 4. Nasal Tolerability Assessment in End-of-Treatment Phase for FPNS
Objective
parameter

Absent (n)

Present (n)

Obstruction

87

2

Inflammation

89

0

Nasal d/c

85

4

Color mucosa

89

0
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DISCUSSION
Davies et al. and Fallon et al. have proven that FPNS provides more rapid and effective
analgesia with a time course more suitable than that of IRMS for treating a BTCP episode. Also,
Fallon et al. helped conclude that FPNS can achieve maximum pain relief quicker that IRMS.
Also, based on the Portenoy et al. study, the minimal need to use rescue medication in and
exceptional nasal tolerability confers effectiveness. All three studies demonstrate safe and
effective pain management with FPNS for BTCP episodes.
FPNS, or PecFent, is already available in several European countries. The efforts of these
studies have contributed to the FDA approval of this intranasal analgesic option for patients
suffering from inadequate pain control. The U.S. FDA approved fentanyl nasal spray (Lazanda)
for patients above 18 years of age with BTCP, and is indicated for patients already receiving
opioid therapy, but who have developed resistance to their current regimen. It is contraindicated
in patients who are intolerant to opioid therapy (not already taking a fixed-schedule of opioids)
due to the possibility of hypoventilation that can occur at any given dose, as well as for patients
with severe renal or hepatic failure. According to the manufacturer, the product is made
available after the completion of a Risk Evaluation and Mitigation Strategy program (REMS) by
healthcare professionals who wish to prescribe or distribute. This measure has been proposed
essentially to minimize the risk for abuse, addiction, overdose, and complications due to
medication errors.7
There are several limitations to all three studies. The short duration of these studies made
it difficult to interpret the relationship between AEs, FPNS use, and a patient’s fixed-schedule
opioid regimen. The complexity of the medical condition of these patients and the differences in
each patient’s background opioid therapy contribute to the overall AE rate. Regardless of this
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flaw, effectiveness of FPNS is suggested by a high percentage of patients opting to continue into
an open-label extension phase after the study (for example, 87% in Portenoy et al study). Also, a
high placebo response was noted regarding the number of patients who did not need additional
rescue medication within the 60 minute interval. A factor complicating this limitation is the
possibility of spontaneous resolution of the BTCP episode at various time endpoints.
Patient acceptability is vital when introducing a new route of administration. It was of
concern that patients may find it difficult to administer, have a bad taste, or lose efficacy by
catching in the back on the throat after administration. However, the subjective patient
acceptability ratings in these studies, combined with the results of the objective nasal
assessments disprove all these concerns. In fact, this intranasal option is of particular interest to
advanced cancer patients who may suffer from mucositis or xerostomia, because they often find
oral formulations difficult or uncomfortable to use.2
CONCLUSION
The evidence provided in this systematic review demonstrates that FPNS surpassed the
therapeutic effects of the gold standard, IRMS, in delivering significantly earlier and clinically
meaningful reductions in pain, as well as providing more complete pain relief throughout the
duration of the BTCP episode. Unlike oral IRMS, the pharmacokinetics of this intranasal option
lends itself to quicker onset of pain relief and quicker total pain relief. Many cancer patients are
treated as outpatients in clinical practice today, and studies have shown that patients often
receive inadequate pain relief due to improper use of rescue medications, in part due to
discouragement of its effectiveness. Proper management of these patients requires a great level
of patient compliance and adherence to treatment plans; therefore, it is important that rescue
medications are very effective, have a rapid onset, are safe, tolerable, and easy to use.
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